Profectus BioSciences, Inc.'s Vesicular Stomatitis Virus-Vectored HIV-1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial
Published: Dec 04, 2012
BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, announced that a phase 1 study has demonstrated the safety and immunogenicity of its recombinant vesicular stomatitis virus (rVSV)-vectored HIV vaccine. VSV is a type of RNA virus that can infect both insects and mammals. It is commonly used in laboratory settings as a gene delivery vector without the potential for integration, a characteristic that provides a safety advantage in vaccine applications. The first studies to demonstrate the potential of rVSV as an HIV vaccine vector were performed in the laboratories of Dr. John K. Rose at Yale University more than a decade ago. The recombinant version used in this clinical study is able to replicate in human cells, but has been attenuated (weakened) so as not to cause illness in animals or humans.